Indonesia to resume use of AstraZeneca coronavirus vaccine
The Peninsula
JAKARTA - Indonesia's Food and Drug agency (BPOM) said on Friday it has approved the usage of AstraZeneca's COVID-19 vaccine after reviewing reports that it had caused blood clots among some recipients in Europe.
The agency said that even though vaccination could lead to "adverse events" following immunisation, "the risk of death from COVID-19 is much higher." "The benefits of giving the AstraZeneca COVID-19 vaccine outweigh the risks," the agency said in a statement.More Related News